DDInter1729 DDInter1581
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.
Sulindac {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Repaglinide
Sulindac {u} (Compound) causes {v} (Side Effect) Pancreatitis
Pancreatitis {u} (Side Effect) is caused by {v} (Compound) Repaglinide
Sulindac {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Repaglinide
Sulindac {u} (Compound) causes {v} (Side Effect) Pancreatitis
Pancreatitis {u} (Side Effect) is caused by {v} (Compound) Nelfinavir
Nelfinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Sulindac {u} (Compound) causes {v} (Side Effect) Chest pain
Chest pain {u} (Side Effect) is caused by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Sulindac {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Repaglinide
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Phentermine
Phentermine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Sulindac {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Dronedarone
Dronedarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Sulindac {u} (Compound) binds {v} (Gene) AKR1B1
AKR1B1 {u} (Gene) is regulated by {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Repaglinide
Sulindac {u} (Compound) binds {v} (Gene) PPARD
PPARD {u} (Gene) is upregulated by {v} (Compound) Vorinostat
Vorinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Sulindac (Compound) binds ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)
Sulindac (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Repaglinide (Compound)
Sulindac (Compound) binds ALB (Gene) and ALB (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Repaglinide (Compound)
Sulindac (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Nelfinavir (Compound) and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Sulindac (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Sulindac (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Repaglinide
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Phentermine (Compound) and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Sulindac (Compound) binds ALB (Gene) and ALB (Gene) is bound by Dronedarone (Compound) and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Sulindac (Compound) binds AKR1B1 (Gene) and AKR1B1 (Gene) is regulated by ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)
Sulindac (Compound) binds PPARD (Gene) and PPARD (Gene) is upregulated by Vorinostat (Compound) and Vorinostat may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide